JUN and Ewing sarcoma: RBM39 has been demonstrated to have a role in several pathways including the transcriptional activation of AP1/Jun and estrogen receptors, and has been associated with colorectal cancers and Ewing sarcoma (Stepanyuk et al., 2016).